Clinical experience with trans-catheter aortic valve implantation at a tertiary hospital in the Republic of Ireland
Language English Country Ireland Media print-electronic
Document type Journal Article
PubMed
31197575
DOI
10.1007/s11845-019-02030-7
PII: 10.1007/s11845-019-02030-7
Knihovny.cz E-resources
- Keywords
- Aortic stenosis, Clinical outcomes, Ireland, TAVI, Trans-catheter aortic valve replacement,
- MeSH
- Aortic Valve surgery MeSH
- Aortic Valve Stenosis surgery MeSH
- Tertiary Care Centers MeSH
- Stroke mortality MeSH
- Kaplan-Meier Estimate MeSH
- Cohort Studies MeSH
- Humans MeSH
- Prospective Studies MeSH
- Registries MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Transcatheter Aortic Valve Replacement methods MeSH
- Treatment Outcome MeSH
- Check Tag
- Humans MeSH
- Male MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Geographicals
- Ireland MeSH
INTRODUCTION: There is a paucity of published data on the clinical experience with trans-catheter aortic valve implantation (TAVI) in the Republic of Ireland. We sought to examine the clinical outcomes of patients with medium-term follow-up treated with TAVI at our institution. METHODS: A prospective TAVI registry was used to assess the baseline demographics, procedural variables and clinical outcomes of patients treated with TAVI between the inception of the programme in 2008 and November 2017. RESULTS: A total of 354 patients (mean age 80.9 ± 8.1 years, 58% male, mean STS score 6.1 ± 4.3%) were treated during the study period. Major in-hospital outcomes included in-lab death (n = 2, 0.6%), stroke (n = 8, 2.2%), device embolisation (n = 4, 1.2%), permanent pacemaker implantation (n = 22, 6.2%) and major vascular complication (n = 2, 0.6%). The median length of hospital stay was 4 days (IQR 2-8 days). The Kaplan-Meier estimate of freedom from death at 30 days and 1 year for the entire cohort was 97 ± 1% and 85.4 ± 2.3%, respectively. Trans-femoral access was associated with a significantly lower rate of death and/or stroke at 1 year compared to trans-apical access (84.9 ± 2.4% versus 60 ± 8.9%, p = 0.0005). There was no significant difference in freedom from death and/or stroke at 1 year between balloon-expandable and self-expanding valves (81.6 ± 2.6% versus 84.4 ± 7.4%, p = 0.63). CONCLUSION: This study documents low complication rates and favourable rates of survival following TAVI in a consecutive series of patients undergoing TAVI at a tertiary referral centre in the Republic of Ireland. These data support the application of this therapy in the Irish context.
Department of Cardiology Mater Misericordiae University Hospital Eccles Street Dublin 7 Ireland
See more in PubMed
N Engl J Med. 2016 Apr 28;374(17):1609-20 PubMed
N Engl J Med. 2014 May 8;370(19):1790-8 PubMed
Eur J Cardiothorac Surg. 2014 Nov;46(5):808-16 PubMed
JAMA. 2014 Apr 16;311(15):1503-14 PubMed
N Engl J Med. 2017 Apr 6;376(14):1321-1331 PubMed
J Am Coll Cardiol. 2015 May 26;65(20):2173-80 PubMed
JACC Cardiovasc Interv. 2016 Nov 14;9(21):2189-2199 PubMed
J Am Coll Cardiol. 2015 Dec 29;66(25):2813-2823 PubMed
J Am Coll Cardiol. 2017 Jul 4;70(1):42-55 PubMed
N Engl J Med. 2011 Jun 9;364(23):2187-98 PubMed
JAMA. 2015 Mar 10;313(10):1019-28 PubMed
Am J Cardiol. 2013 Jan 1;111(1):94-9 PubMed
Eur J Cardiothorac Surg. 2012 Apr;41(4):734-44; discussion 744-5 PubMed
Ann Thorac Surg. 2016 Aug;102(2):573-9 PubMed
Anaesthesia. 2011 Nov;66(11):977-82 PubMed
Eur Heart J. 2017 Sep 21;38(36):2739-2791 PubMed
Circ Cardiovasc Interv. 2017 Jul;10(7):null PubMed
Circulation. 2015 Mar 31;131(13):1181-90 PubMed
Int J Cardiol Heart Vasc. 2017 Jul 07;16:1-3 PubMed
Ann Thorac Surg. 2014 Mar;97(3):796-802 PubMed
J Am Coll Cardiol. 2016 Oct 11;68(15):1637-1647 PubMed
Eur Heart J. 2012 Apr;33(7):822-8, 828a, 828b PubMed
J Thorac Cardiovasc Surg. 2013 Jan;145(1):6-23 PubMed
